Trattamento del "persistent postmastectomy pain" con Lidocaina cerotto 5%

Translated title of the contribution: Treatment of persistent postmastectomy pain with 5% Lidocaine medicated plaster

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Persistent postmastectomy pain (PPMP) syndrome is characterized by neuropathic pain that develops following surgery in breast cancer patients. The reported incidence of PPMP ranges between 30% and 50% and is estimated to increase as the number of women surviving cancer continues to rise. Though effective, today's drug treatments are poorly tolerated, limiting their use and reducing adherence to therapy. Since neuropathic pain is localized, international guidelines suggest that topical treatment with 5% Lidocaine medicated plaster either alone or combined with systemic drugs can be considered for pain management. In this retrospective study we reviewed the medical records of 11 patients treated with 5% lidocaine medicated plaster for moderate-to-severe PPMP at our institute between November 2013 and October 2014. Analysis showed that treatment with 5% Lidocaine medicated plaster, either alone or in combination with systemic drugs, achieved significant pain control already after the first week of therapy. The effectiveness and tolerability of 5% Lidocaine medicated plaster we observed suggests that it is a viable option in the management of PPMP.

Original languageItalian
Pages (from-to)147-153
Number of pages7
JournalMinerva Chirurgica
Volume70
Issue number2
Publication statusPublished - Apr 1 2015

Fingerprint

Lidocaine
Pain
Neuralgia
Pharmaceutical Preparations
Therapeutics
Pain Management
Medical Records
Retrospective Studies
Guidelines
Breast Neoplasms
Incidence
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{6aece052771b4167be870f6083e67a5c,
title = "Trattamento del {"}persistent postmastectomy pain{"} con Lidocaina cerotto 5{\%}",
abstract = "Persistent postmastectomy pain (PPMP) syndrome is characterized by neuropathic pain that develops following surgery in breast cancer patients. The reported incidence of PPMP ranges between 30{\%} and 50{\%} and is estimated to increase as the number of women surviving cancer continues to rise. Though effective, today's drug treatments are poorly tolerated, limiting their use and reducing adherence to therapy. Since neuropathic pain is localized, international guidelines suggest that topical treatment with 5{\%} Lidocaine medicated plaster either alone or combined with systemic drugs can be considered for pain management. In this retrospective study we reviewed the medical records of 11 patients treated with 5{\%} lidocaine medicated plaster for moderate-to-severe PPMP at our institute between November 2013 and October 2014. Analysis showed that treatment with 5{\%} Lidocaine medicated plaster, either alone or in combination with systemic drugs, achieved significant pain control already after the first week of therapy. The effectiveness and tolerability of 5{\%} Lidocaine medicated plaster we observed suggests that it is a viable option in the management of PPMP.",
author = "Cruto, {M. E.} and E. Baricocchi and M. Battistella and F. Bona and G. Giacoletto and A. Iacobellis and N. Moselli and G. Palomba and E. Sardo and M. Savojardo and L. Suita and E. Zocca and F. Debernardi",
year = "2015",
month = "4",
day = "1",
language = "Italian",
volume = "70",
pages = "147--153",
journal = "Minerva Chirurgica",
issn = "0026-4733",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Trattamento del "persistent postmastectomy pain" con Lidocaina cerotto 5%

AU - Cruto, M. E.

AU - Baricocchi, E.

AU - Battistella, M.

AU - Bona, F.

AU - Giacoletto, G.

AU - Iacobellis, A.

AU - Moselli, N.

AU - Palomba, G.

AU - Sardo, E.

AU - Savojardo, M.

AU - Suita, L.

AU - Zocca, E.

AU - Debernardi, F.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Persistent postmastectomy pain (PPMP) syndrome is characterized by neuropathic pain that develops following surgery in breast cancer patients. The reported incidence of PPMP ranges between 30% and 50% and is estimated to increase as the number of women surviving cancer continues to rise. Though effective, today's drug treatments are poorly tolerated, limiting their use and reducing adherence to therapy. Since neuropathic pain is localized, international guidelines suggest that topical treatment with 5% Lidocaine medicated plaster either alone or combined with systemic drugs can be considered for pain management. In this retrospective study we reviewed the medical records of 11 patients treated with 5% lidocaine medicated plaster for moderate-to-severe PPMP at our institute between November 2013 and October 2014. Analysis showed that treatment with 5% Lidocaine medicated plaster, either alone or in combination with systemic drugs, achieved significant pain control already after the first week of therapy. The effectiveness and tolerability of 5% Lidocaine medicated plaster we observed suggests that it is a viable option in the management of PPMP.

AB - Persistent postmastectomy pain (PPMP) syndrome is characterized by neuropathic pain that develops following surgery in breast cancer patients. The reported incidence of PPMP ranges between 30% and 50% and is estimated to increase as the number of women surviving cancer continues to rise. Though effective, today's drug treatments are poorly tolerated, limiting their use and reducing adherence to therapy. Since neuropathic pain is localized, international guidelines suggest that topical treatment with 5% Lidocaine medicated plaster either alone or combined with systemic drugs can be considered for pain management. In this retrospective study we reviewed the medical records of 11 patients treated with 5% lidocaine medicated plaster for moderate-to-severe PPMP at our institute between November 2013 and October 2014. Analysis showed that treatment with 5% Lidocaine medicated plaster, either alone or in combination with systemic drugs, achieved significant pain control already after the first week of therapy. The effectiveness and tolerability of 5% Lidocaine medicated plaster we observed suggests that it is a viable option in the management of PPMP.

UR - http://www.scopus.com/inward/record.url?scp=84948067978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948067978&partnerID=8YFLogxK

M3 - Articolo

VL - 70

SP - 147

EP - 153

JO - Minerva Chirurgica

JF - Minerva Chirurgica

SN - 0026-4733

IS - 2

ER -